Jan 16 (Reuters) - The U.S. Food and Drug Administration
on Thursday declined to approve Atara Biotherapeutics' ( ATRA )
cancer therapy, chemically called tabelecleucel.
The company was seeking approval for the therapy to treat
patients with Epstein-Barr virus positive post-transplant
lymphoproliferative disease (EBV+ PTLD).